North America Melanoma Therapeutics Market Size & Outlook
Related Markets
North America melanoma therapeutics market highlights
- The North America melanoma therapeutics market generated a revenue of USD 2,256.2 million in 2024.
- The market is expected to grow at a CAGR of 9.8% from 2025 to 2030.
- In terms of segment, immunotherapies was the largest revenue generating product in 2024.
- Immunotherapies is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, Mexico is expected to register the highest CAGR from 2025 to 2030.
North America data book summary
| Market revenue in 2024 | USD 2,256.2 million |
| Market revenue in 2030 | USD 3,938.3 million |
| Growth rate | 9.8% (CAGR from 2025 to 2030) |
| Largest segment | Immunotherapies |
| Fastest growing segment | Immunotherapies |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Immunotherapies, Targeted Therapies, Chemotherapies, Radiation therapy |
| Key market players worldwide | Bristol-Myers Squibb Co, AstraZeneca PLC, Novartis AG ADR, Merck & Co Inc, Amgen Inc, Abbott Laboratories, Roche Holding AG |
Other key industry trends
- In terms of revenue, North America region accounted for 38.7% of the global melanoma therapeutics market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 2,775.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Melanoma Therapeutics Market Scope
Melanoma Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Bristol-Myers Squibb Co | View profile | 34100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | https://www.bms.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Roche Holding AG | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
| Abbott Laboratories | View profile | 114000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | https://www.abbottinvestor.com |
| Amgen Inc | View profile | 26700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | https://www.amgen.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
North America melanoma therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to melanoma therapeutics market will help companies and investors design strategic landscapes.
Immunotherapies was the largest segment with a revenue share of 45.42% in 2024. Horizon Databook has segmented the North America melanoma therapeutics market based on immunotherapies, targeted therapies, chemotherapies, radiation therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to North America melanoma therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America melanoma therapeutics market databook
-
Our clientele includes a mix of melanoma therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America melanoma therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into North America melanoma therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
North America melanoma therapeutics market size, by country, 2018-2030 (US$M)
North America Melanoma Therapeutics Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
